Piaza: Non-interventional Study on Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMML (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder). 7. Juni 2015 Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Neidig, C., Teichmann, B., Harde, J., Trarbach, T., 2015. Oncol Res Treat 38 (suppl.5)(P235), 70. doi:10.1159/000439070 Abstract Do we miss changes in Quality of Life? Data from the LuLife project in patients with non-small cell lung cancer in Germany. von Verschuer, U., Sandner, R., Däßler, K.-U., Tessen, H.W., Münz, M., Spring, L., Jänicke, M., Marschner, N., 2015. Oncol Res Treat 38 (suppl 5)(V45), 13. Weiterlesen Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany. Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Meinerz, Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Meinerz, W., 2015. Annual… Weiterlesen